Spleen scan could spare PBC patients unnecessary scopes
NCT ID NCT07319169
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether measuring spleen stiffness with a simple ultrasound-like test (FibroScan) can help doctors better predict complications in people with Primary Biliary Cholangitis (PBC). Researchers will follow 125 adults already on standard treatment, adding a spleen stiffness measurement and two questionnaires to their regular check-ups every 6 months. The goal is to see if this extra measurement can identify who is at low risk for serious liver problems, potentially avoiding uncomfortable and costly endoscopic exams.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 125 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥18y * Out-patient, followed at the UZ Brussels * Diagnosis of PBC based on cholestasis, AMA positivity and/or biopsy. * Under treatment with ursodeoxycholic acid and/or bezafibrate Exclusion Criteria: * \<18y * Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Primary biliary cholangitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
UZ Brussel
Brussels, 1090, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord stem cells rescue a stubborn liver disease?
- Can a new drug rescue the liver when standard therapy fails?
- A painless spleen scan could spot deadly vein bleeding risk without endoscopy
- Artificial intelligence may help decide who gets a liver first
- AI may outsmart current system for liver transplant priority
- Can a smartwatch help manage a rare liver disease? stanford study investigates